The role of biofactors in the prevention and treatment of age-related diseases.
Aged
Cardiovascular Diseases
/ genetics
Dementia
/ genetics
Diabetes Mellitus
/ genetics
Dietary Fiber
/ administration & dosage
Dietary Supplements
Epigenesis, Genetic
Fatty Acids, Omega-3
/ administration & dosage
Folic Acid
/ administration & dosage
Humans
Neoplasms
/ genetics
Non-alcoholic Fatty Liver Disease
/ genetics
Thiamine
/ administration & dosage
Thioctic Acid
/ administration & dosage
Vitamin D
/ administration & dosage
Vitamin E
/ administration & dosage
biofactor definition
cancer epigenetics
cardiovascular diseases
diabetes mellitus
micronutrients
neurodegenerative diseases
nonalcoholic fatty liver disease
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
03
03
2021
received:
21
09
2020
accepted:
11
03
2021
pubmed:
28
3
2021
medline:
7
1
2022
entrez:
27
3
2021
Statut:
ppublish
Résumé
The present demographic changes toward an aging society caused a rise in the number of senior citizens and the incidence and burden of age-related diseases (such as cardiovascular diseases [CVD], cancer, nonalcoholic fatty liver disease [NAFLD], diabetes mellitus, and dementia), of which nearly half is attributable to the population ≥60 years of age. Deficiencies in individual nutrients have been associated with increased risks for age-related diseases and high intakes and/or blood concentrations with risk reduction. Nutrition in general and the dietary intake of essential and nonessential biofactors is a major determinant of human health, the risk to develop age-related diseases, and ultimately of mortality in the older population. These biofactors can be a cost-effective strategy to prevent or, in some cases, even treat age-related diseases. Examples reviewed herein include omega-3 fatty acids and dietary fiber for the prevention of CVD, α-tocopherol (vitamin E) for the treatment of biopsy-proven nonalcoholic steatohepatitis, vitamin D for the prevention of neurodegenerative diseases, thiamine and α-lipoic acid for the treatment of diabetic neuropathy, and the role of folate in cancer epigenetics. This list of potentially helpful biofactors in the prevention and treatment of age-related diseases, however, is not exhaustive and many more examples exist. Furthermore, since there is currently no generally accepted definition of the term biofactors, we here propose a definition that, when adopted by scientists, will enable a harmonization and consistent use of the term in the scientific literature.
Substances chimiques
Dietary Fiber
0
Fatty Acids, Omega-3
0
Vitamin D
1406-16-2
Vitamin E
1406-18-4
Thioctic Acid
73Y7P0K73Y
Folic Acid
935E97BOY8
Thiamine
X66NSO3N35
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-550Informations de copyright
© 2021 The Authors. BioFactors published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.
Références
Mathers CD, Stevens GA, Boerma T, White RA, Tobias MI. Causes of international increases in older age life expectancy. Lancet (London, England). 2015;385:540-8.
Ageing and health. www.who.int/news-room/fact-sheets/detail/ageing-and-health.
United Nations Population Division | Department of Economic and Social Affairs. https://population.un.org.
Scully T. Demography: to the limit. Nature. 2012;492:S2-3.
Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O'Donnell M, Sullivan R, et al. The burden of disease in older people and implications for health policy and practice. Lancet (London, England). 2015;385:549-62.
Ames BN. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci U S A. 2006;103:17589-94.
Ames BN. Prolonging healthy aging: longevity vitamins and proteins. Proc Natl Acad Sci U S A. 2018;115:10836-44.
Knekt P, Kumpulainen J, Järvinen R, Rissanen H, Heliövaara M, Reunanen A, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002;76:560-8.
Chen G-C, Yang J, Eggersdorfer M, Zhang W, Qin L-Q. N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis. Sci Rep. 2016;6:28165.
Harris WS, Luo J, Pottala JV, Espeland MA, Margolis KL, Manson JE, et al. Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative memory study. J Clin Lipidol. 2017;11:250-259.e5.
Frank J, Fukagawa NK, Bilia AR, Johnson EJ, Kwon O, Prakash V, et al. Terms and nomenclature used for plant-derived components in nutrition and related research: efforts toward harmonization. Nutr Rev. 2020;78:451-8.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Hanahan D, Weinberg RA. Hallmarks of Cancer: the next generation. Cell. 2011;144:646-74.
Fardi M, Solali S, Farshdousti Hagh M. Epigenetic mechanisms as a new approach in cancer treatment: an updated review. Genes Diseases. 2018;5:304-11.
Berdasco M, Esteller M. Aberrant epigenetic landscape in Cancer: how cellular identity Goes awry. Dev Cell. 2010;19:698-711.
Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315-22.
Vidal E, Sayols S, Moran S, Guillaumet-Adkins A, Schroeder MP, Royo R, et al. A DNA methylation map of human cancer at single base-pair resolution. Oncogene. 2017;36:5648-57.
Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Bäcker A, et al. Epigenetic impacts of ascorbate on human metastatic melanoma cells. Front Oncol. 2014;4:227.
Negri A, Naponelli V, Rizzi F, Bettuzzi S. Molecular targets of Epigallocatechin-Gallate (EGCG): a special focus on signal transduction and Cancer. Nutrients. 2018;10:1936.
Liu Y, Zhou J, Hu Y, Wang J, Yuan C. Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter. Mol Cell Biochem. 2017;425:47-58.
Blakley RL. IUPAC-IUB joint commission on biochemical nomenclature (JCBN). Nomenclature and symbols for folic acid and related compounds. Recommendations 1986. Eur J Biochem. 1987;168:251-3.
Zheng Y, Cantley LC. Toward a better understanding of folate metabolism in health and disease. J Exp Med. 2019;216:253-66.
McNulty H, Pentieva K, Hoey L, Strain JJ, Ward M. Nutrition throughout life: folate. Int J Vitam Nutr Res. 2012;82:348-54.
McNulty H, Ward M, Hoey L, Hughes CF, Pentieva K. Addressing optimal folate and related B-vitamin status through the lifecycle: health impacts and challenges. Proc Nutr Soc. 2019;78:449-62.
Perła-Kaján J, Jakubowski H. Dysregulation of epigenetic mechanisms of gene expression in the pathologies of hyperhomocysteinemia. IJMS. 2019;20:3140.
Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for Folate's role. Adv Nutr. 2012;3:21-38.
Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Alternat Med Rev. 2003;8:7-19.
Pieroth R, Paver S, Day S, Lammersfeld C. Folate and its impact on Cancer risk. Curr Nutr Rep. 2018;7:70-84.
Lin HL, An QZ, Wang QZ, Liu CX. Folate intake and pancreatic cancer risk: an overall and dose-response meta-analysis. Public Health. 2013;127:607-13.
He H, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological studies. Int J Food Sci Nutr. 2014;65:286-92.
Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (London, England). 2013;381:1029-36.
Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M. Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open. 2012;2:e000653.
Mahmoud A, Ali M. Methyl donor micronutrients that modify DNA methylation and Cancer outcome. Nutrients. 2019;11:608.
Kotsopoulos J, Sohn K-J, Kim Y. Postweaning dietary folate deficiency provided through childhood to puberty permanently increases genomic DNA methylation in adult rat liver. J Nutr. 2008;138:703-9.
Zhang Y-F, Shi W-W, Gao H-F, Zhou L, Hou A-J, Zhou YH. Folate intake and the risk of breast Cancer: a dose-response meta-analysis of prospective studies. PLoS One. 2014;9:e100044.
Duman EA, Kriaucionis S, Dunn JJ, Hatchwell E. A simple modification to the luminometric methylation assay to control for the effects of DNA fragmentation. Biotechniques. 2015;58:262-4.
Cardiovascular diseases (CVDs). www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
Wallert M, Schmölz L, Galli F, Birringer M, Lorkowski S. Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. Redox Biol. 2014;2:495-503.
Meier T, Gräfe K, Senn F, Sur P, Stangl GI, Dawczynski C, et al. Cardiovascular mortality attributable to dietary risk factors in 51 countries in the WHO European region from 1990 to 2016: a systematic analysis of the global burden of disease study. Eur J Epidemiol. 2019;34:37-55.
Afshin A, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, et al. The impact of dietary habits and metabolic risk factors on cardiovascular and diabetes mortality in countries of the Middle East and North Africa in 2010: a comparative risk assessment analysis. BMJ Open. 2015;5:e006385.
Nadir MA, Szwejkowski BR, Witham MD. Vitamin D and cardiovascular prevention. Cardiovasc Ther. 2010;28:e5-e12.
Jenkins DJ, Spence JD, Giovannucci EL, Kim Y, Josse R, Vieth R, et al. Supplemental vitamins and minerals for CVD prevention and treatment. J Am Coll Cardiol. 2018;71:2570-84.
NVSII: Max Rubner-Institut. https://www.mri.bund.de/de/institute/ernaehrungsverhalten/forschungsprojekte/nvsii/.
Skeie G, Braaten T, Hjartåker A, Lentjes M, Amiano P, Jakszyn P, et al. Use of dietary supplements in the European prospective investigation into Cancer and nutrition calibration study. Eur J Clin Nutr. 2009;63:S226-38.
Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016;316:1464-74.
Li K, Wang X-F, Li D-Y, Chen Y-C, Zhao L-J, Liu XG, et al. The good, the bad, and the ugly of calcium supplementation: a review of calcium intake on human health. Clin Interv Aging. 2018;13:2443-52.
Referenzwerte. www.dge.de/wissenschaft/referenzwerte.
Nutrition Education Resources & Materials. https://www.fda.gov/food/food-labeling-nutrition/nutrition-education-resources-materials.
Scientific Opinion on the Tolerable Upper Intake Level of calcium. https://www.efsa.europa.eu/de/efsajournal/pub/2814.
Anderson JJ, Kruszka B, Delaney JA, He K, Burke GL, Alonso A, et al. Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the multi-ethnic study of atherosclerosis (MESA). J Am Heart Assoc. 2016;5:e003815.
Kopecky SL, Bauer DC, Gulati M, Nieves JW, Singer AJ, Toth PP, et al. Lack of evidence linking calcium with or without vitamin D supplementation to cardiovascular disease in generally healthy adults: a clinical guideline from the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Ann Intern Med. 2016;165:867-8.
de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95:1-46.
Al Alawi AM, Majoni SW, Falhammar H. Magnesium and human health: perspectives and research directions. Int J Endocrinol. 2018;2018:1-17.
Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J. 1984;108:188-93.
Murck H. Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back. J Psychiatr Res. 2013;47:955-65.
Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension (Dallas, Tex: 1979). 2016;68:324-33.
Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens. 2002;15:691-6.
Costello RB, Elin RJ, Rosanoff A, Wallace TC, Guerrero-Romero F, Hruby A, et al. Perspective: the case for an evidence-based reference interval for serum magnesium: the time has come. Adv Nutr (Bethesda, Md.). 2016;7:977-93.
Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol. 2009;134:145-7.
Kisters KK, Gremmler B, Grober U. Natriuretic peptides, hypertension, heart insufficiency and magnesium. Adv Tech Biol Med. 2015;3:134.
Rosenfeldt FL, Richards SM, Lin Z, Pepe S, Conyers RA. Mechanism of cardioprotective effect of orotic acid. Cardiovasc Drugs Ther. 1998;12 Suppl 2:159-70.
Del Gobbo LC, Imamura F, Wu JHY, Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160-73.
Fang X, Liang C, Li M, Montgomery S, Fall K, Aaseth J, et al. Dose-response relationship between dietary magnesium intake and cardiovascular mortality: a systematic review and dose-based meta-regression analysis of prospective studies. J Trace Elem Med Biol. 2016;38:64-73.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
Berridge MJ. Vitamin D deficiency accelerates ageing and age-related diseases: a novel hypothesis. J Physiol. 2017;595:6825-36.
Pilz S, Zittermann A, Trummer C, Theiler-Schwetz V, Lerchbaum E, Keppel MH, et al. Vitamin D testing and treatment: a narrative review of current evidence. Endocr Connect. 2019;8:R27-43.
Pilz S, März W, Cashman KD, Kiely ME, Whiting SJ, Holick MF, et al. Rationale and plan for vitamin D food fortification: a review and guidance paper. Front Endocrinol. 2018;9:373.
Tolerable upper intake levels for vitamins and minerals. http://www.efsa.europa.eu/sites/default/files/efsa_rep/blobserver_assets/ndatolerableuil.pdf.
Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W. Vitamin D and cardiovascular disease prevention. Nat Rev Cardiol. 2016;13:404-17.
Grübler MR, März W, Pilz S, Grammer TB, Trummer C, Müllner C, et al. Vitamin-D concentrations, cardiovascular risk and events - a review of epidemiological evidence. Rev Endocr Metab Disord. 2017;18:259-72.
Wang J, Zhou JJ, Robertson GR, Lee VW. Vitamin D in vascular calcification: a double-edged sword? Nutrients. 2018;10:652.
Beveridge LA, Khan F, Struthers AD, Armitage J, Barchetta I, Bressendorff I, et al. Effect of vitamin D supplementation on markers of vascular function: a systematic review and individual participant meta-analysis. J Am Heart Assoc. 2018;7:e008273.
Swart KM, Lips P, Brouwer IA, Jorde R, Heymans MW, Grimnes G, et al. Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018;107:1043-53.
Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015;175:745-54.
Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M, et al. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr. 2014;100:746-55.
Jiang W-L, Gu H-B, Zhang Y-F, Xia Q-Q, Qi J, Chen JC. Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol. 2016;39:56-61.
Zittermann A. Vitamin D status, supplementation and cardiovascular disease. Anticancer Res. 2018;38:1179-86.
Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33:231-48.
Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-57.
Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease. Circulation. 2017;135:e867-84.
Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and Cancer. N Engl J Med. 2019;380:23-32.
Goel A, Pothineni N, Singhal M, Paydak H, Saldeen T, Mehta J. Fish, fish oils and Cardioprotection: promise or fish tale? Int J Mol Sci. 2018;19:3703.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22.
Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268-80.
Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis. 2008;200:135-40.
Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep. 2009;26:1001-43.
USDA Database for the Flavonoid Content of Selected Foods: Release 3.2. (2015): https://data.nal.usda.gov/dataset/usda-database-flavonoid-content-selected-foods-release-32-november-2015.
Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45:2179-205.
Erdman JW, Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, et al. Flavonoids and heart health: proceedings of the ILSI North America flavonoids workshop, may 31-June 1, 2005, Washington, DC. J Nutr. 2007;137:718S-37S.
Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:2073S-85S.
Zamora-Ros R, Forouhi NG, Sharp SJ, González CA, Buijsse B, Guevara M, et al. Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr. 2014;144:335-43.
Wang X, Ouyang YY, Liu J, Zhao G. Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr. 2014;111:1-11.
Boesch-Saadatmandi C, Egert S, Schrader C, Coumoul X, Coumol X, Muller MJ, et al. Effect of quercetin on paraoxonase 1 activity--studies in cultured cells, mice and humans. J Physiology Pharmacol. 2010;61:99-105.
Boesch-Saadatmandi C, Loboda A, Wagner AE, Stachurska A, Jozkowicz A, Dulak J, et al. Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155. J Nutr Biochem. 2011;22:293-9.
Boesch-Saadatmandi C, Wagner AE, Wolffram S, Rimbach G. Effect of quercetin on inflammatory gene expression in mice liver in vivo - role of redox factor 1, miRNA-122 and miRNA-125b. Pharmacol Res. 2012;65:523-30.
Brüll V, Burak C, Stoffel-Wagner B, Wolffram S, Nickenig G, Müller C, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. Br J Nutr. 2015;114:1263-77.
Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr. 2010;140:278-84.
Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102:1065-74.
Serban M-C, Sahebkar A, Zanchetti A, Mikhailidis DP, Howard G, Antal D, et al. Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5:e002713.
Huang H, Liao D, Dong Y, Pu R. Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis. Nutr Rev. 2020;78:615-26.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-324.
Larson AJ, Symons JD, Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv Nutr (Bethesda, MD). 2012;3:39-46.
Boots AW, Wilms LC, Swennen ELR, Kleinjans JCS, Bast A, Haenen GRMM. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition (Burbank, Los Angeles County, Calif). 2008;24:703-10.
Sato S, Mukai Y. Modulation of chronic inflammation by quercetin: the beneficial effects on obesity. J Inflamm Res. 2020;13:421-31.
Tabrizi R, Tamtaji OR, Mirhosseini N, Lankarani KB, Akbari M, Heydari ST, et al. The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60:1855-68.
Brüll V, Burak C, Stoffel-Wagner B, Wolffram S, Nickenig G, Müller C, et al. No effects of quercetin from onion skin extract on serum leptin and adiponectin concentrations in overweight-to-obese patients with (pre-) hypertension: a randomized double-blinded, placebo-controlled crossover trial. Eur J Nutr. 2017;56:2265-75.
Mohammadi-Sartang M, Mazloom Z, Sherafatmanesh S, Ghorbani M, Firoozi D. Effects of supplementation with quercetin on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2017;71:1033-9.
Guo W, Gong X, Li M. Quercetin actions on lipid profiles in overweight and obese individuals: a systematic review and meta-analysis. Curr Pharm Des. 2019;25:3087-95.
Sahebkar A. Effects of quercetin supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2017;57:666-76.
Menezes R, Rodriguez-Mateos A, Kaltsatou A, González-Sarrías A, Greyling A, Giannaki C, et al. Impact of flavonols on cardiometabolic biomarkers: a meta-analysis of randomized controlled human trials to explore the role of inter-individual variability. Nutrients. 2017;9:117.
Behall KM, Scholfield DJ, Hallfrisch J. Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women. Am J Clin Nutr. 2004;80:1185-93.
AbuMweis SS, Jew S, Ames NP. β-Glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr. 2010;64:1472-80.
Ho HVT, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, et al. The effect of oat β -glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br J Nutr. 2016;116:1369-82.
Tang G, Wang D, Long J, Yang F, Si L. Meta-analysis of the association between whole grain intake and coronary heart disease risk. Am J Cardiol. 2015;115:625-9.
Reynolds A, Mann J, Cummings J, Winter N, Mete E, te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393:434-45.
EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of health claims related to beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol concentrations (ID 1236, 1299), increase in satiety leading to a reduction in energy intake (ID 851, 852), reduction of post-prandial glycaemic responses (ID 821, 824), and “digestive function” (ID 850) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. ESFA J. 2015;9: 2207.
Pastor-Villaescusa B, Rangel-Huerta OD, Aguilera CM, Gil A. A systematic review of the efficacy of bioactive compounds in cardiovascular disease: carbohydrates, active lipids and nitrogen compounds. Ann Nutr Metab. 2015;66:168-81.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md.). 2018;67:123-33.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, MD). 2016;64:73-84.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with Long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10.
Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221-35.
Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649-59.
Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810-7.
Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (Baltimore, MD). 2010;51:595-602.
Kleiner DE, Brunt EM, van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2005;41:1313-21.
Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:46-53.
van Wagner LB, Armstrong MJ. Lean NAFLD: a not so benign condition? Hepatol Commun. 2017;2:5-8.
Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321-50.
Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol. 2002;37:56-62.
Feldstein AE, Lopez R, Tamimi TA-R, Yerian L, Chung Y-M, Berk M, et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51:3046-54.
Evans HM, Bishop KS. On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science (New York, NY). 1922;56:650-1.
Traber MG, Burton GW, Ingold KU, Kayden HJ. RRR- and SRR-alpha-tocopherols are secreted without discrimination in human chylomicrons, but RRR-alpha-tocopherol is preferentially secreted in very low density lipoproteins. J Lipid Res. 1990;31:675-85.
Raso GM, Esposito E, Iacono A, Pacilio M, Cuzzocrea S, Canani RB, et al. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Eur J Pharmacol. 2009;604:125-31.
Iida C, Fujii K, Koga E, Washino Y, Kitamura Y, Ichi I, et al. Effect of α-tocopherol on carbon tetrachloride intoxication in the rat liver. Arch Toxicol. 2009;83:477-83.
Podszun MC, Grebenstein N, Spruss A, Schlueter T, Kremoser C, Bergheim I, et al. Dietary α-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate CD36 protein in the liver of Guinea pigs. J Nutr Biochem. 2014;25:573-9.
Klaebel JH, Rakipovski G, Andersen B, Lykkesfeldt J, Tveden-Nyborg P. Dietary intervention accelerates NASH resolution depending on inflammatory status with minor additive effects on hepatic injury by vitamin E supplementation. Antioxidants. 2020;9:808.
Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015;1:275-84.
Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B. Pathology of the liver in obese and diabetic Ob/Ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol. 2011;92:413-21.
Chung M-Y, Yeung SF, Park HJ, Volek JS, Bruno RS. Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J Nutr Biochem. 2010;21:1200-6.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Dia Care. 2019;42:1481-8.
Lavine JE, Schwimmer JB, van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659-68.
Violet P-C, Ebenuwa IC, Wang Y, Niyyati M, Padayatty SJ, Head B, et al. Vitamin E sequestration by liver fat in humans. JCI insight. 2020;5:e133309.
Podszun MC, Jakobi M, Birringer M, Weiss J, Frank J. The long chain α-tocopherol metabolite α-13'-COOH and γ-tocotrienol induce P-glycoprotein expression and activity by activation of the pregnane X receptor in the intestinal cell line LS 180. Mol Nutr Food Res. 2017;61:1600605.
Pein H, Ville A, Pace S, Temml V, Garscha U, Raasch M, et al. Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase. Nat Commun. 2018;9:3834.
Podszun MC, Chung J-Y, Ylaya K, Kleiner DE, Hewitt SM, Rotman Y. 4-HNE immunohistochemistry and image analysis for detection of lipid peroxidation in human liver samples using vitamin E treatment in NAFLD as a proof of concept. J Histochem Cytochem. 2020;68:635-43.
Podszun MC, Alawad AS, Lingala S, Morris N, Huang W-CA, Yang S, et al. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biol. 2020;37:101710.
Vadarlis A, Antza C, Bakaloudi DR, Doundoulakis I, Kalopitas G, Samara M, et al. Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36: 311-19.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, MD). 2018;67:328-57.
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology (Baltimore, MD). 2020;71:495-509.
Wang Y, Ho C-T. Polyphenolic chemistry of tea and coffee: a century of progress. J Agric Food Chem. 2009;57:8109-14.
Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr Rev. 2012;70:41-56.
Bruno RS, Dugan CE, Smyth JA, DiNatale DA, Koo SI. Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J Nutr. 2008;138:323-31.
Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (−)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr. 2008;138:1677-83.
Gan L, Meng Z, Xiong R, Guo J, Lu X, Zheng ZW, et al. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice. Acta Pharmacol Sin. 2015;36:597-605.
Fukuzawa Y, Kapoor MP, Yamasaki K, Okubo T, Hotta Y, Juneja LR. Effects of green tea catechins on nonalcoholic steatohepatitis (NASH) patients. J Funct Foods. 2014;9:48-59.
Frank J, George TW, Lodge JK, Rodriguez-Mateos AM, Spencer JPE, Minihane AM, et al. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J Nutr. 2009;139:58-62.
Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (−)-epigallocatechin-3-gallate in mice. Food Chem Toxicol. 2010;48:409-16.
Wang D, Wang Y, Wan X, Yang CS, Zhang J. Green tea polyphenol (−)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway. Toxicol Appl Pharmacol. 2015;283:65-74.
Yu Z, Samavat H, Dostal AM, Wang R, Torkelson CJ, Yang CS, et al. Effect of green tea supplements on liver enzyme elevation: results from a randomized intervention study in the United States. Cancer Prev Res (Phila). 2017;10:571-9.
Younes M, Aggett P, Aguilar F, Crebelli R, Dusemund B, Filipič M, et al. Scientific opinion on the safety of green tea catechins. EFS2. 2018;16:e05239.
Siegel AB, Stebbing J. Milk thistle: early seeds of potential. Lancet Oncol. 2013;14:929-30.
Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002;97:2391-7.
Lee JI, Narayan M, Barrett JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;845:95-103.
Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Translat Res. 2016;8:1073-81.
Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8:35-44.
Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Petrella A, Tamborra R, et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2010;332:922-32.
Velussi M, Cernigoi AM, Ariella DM, Dapas F, Caffau C, Zilli M. Long-term (23 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871-9.
Aller R, Izaola O, Gómez S, Tafur C, González G, Berroa E, et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19:3118-24.
Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease. Medicine. 2017;96:e9061.
Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of Silymarin for the treatment of nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940-1949.e8.
Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Alternat Med Rev. 2011;16:239-49.
Nobili V, Carpino G, Alisi A, de Vito R, Franchitto A, Alpini G, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014;9:e88005.
Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the welcome* study. Hepatology (Baltimore, MD). 2014;60:1211-21.
Nogueira MA, Oliveira CP, Ferreira Alves VA, Stefano JT, Rodrigues LSDR, Torrinhas RS, et al. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. Clin Nutri (Edinburgh, Scotland). 2016;35:578-86.
He X-X, Wu X-L, Chen R-P, Chen C, Liu X-G, Wu BJ, et al. Effectiveness of Omega-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. PLoS One. 2016;11:e0162368.
WHO. World report on ageing and health. Geneva: WHO; 2015.
Drachman DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 2014;10:372-80.
Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387-98.
Lansdall CJ. An effective treatment for Alzheimer's disease must consider both amyloid and tau. Bioscience Horizons. 2014;7:hzu002.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alz Res Therapy. 2017;9:795.
Amanatkar HR, Papagiannopoulos B, Grossberg GT. Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies. Expert Rev Neurother. 2016;17:7-16.
van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2019;76:1219-229.
Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, et al. Effect of Idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018;319:130-42.
Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, et al. Targeting prodromal Alzheimer disease with Avagacestat. JAMA Neurol. 2015;72:1324-33.
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of Verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380:1408-20.
Brini S, Sohrabi HR, Peiffer JJ, Karrasch M, Hämäläinen H, Martins RN, et al. Physical activity in preventing Alzheimer's disease and cognitive decline: a narrative review. Sports Med (Auckland, NZ). 2018;48:29-44.
Shlisky J, Bloom DE, Beaudreault AR, Tucker KL, Keller HH, Freund-Levi Y, et al. Nutritional considerations for healthy aging and reduction in age-related chronic disease. Adv Nutr. 2017;8:17.2-26.
Rege SD, Geetha T, Broderick TL, Babu JR. Can diet and physical activity limit Alzheimer's disease risk? Curr Alzheimer Res. 2017;14:76-93.
Hill E, Goodwill AM, Gorelik A, Szoeke C. Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis. Neurobiol Aging. 2019;76:45-52.
Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun. 2016;7:11934.
Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr. 2005;45:287-306.
Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP. Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria. Mol Neurobiol. 2012;46:161-78.
Gaudreault R, Mousseau N. Mitigating Alzheimer's disease with natural polyphenols: a review. Curr Alzheimer Res. 2019;16:529-43.
Shukitt-Hale B, Carey AN, Jenkins D, Rabin BM, Joseph JA. Beneficial effects of fruit extracts on neuronal function and behavior in a rodent model of accelerated aging. Neurobiol Aging. 2007;28:1187-94.
Krikorian R, Boespflug EL, Fleck DE, Stein AL, Wightman JD, Shidler MD, et al. Concord grape juice supplementation and neurocognitive function in human aging. J Agric Food Chem. 2012;60:5736-42.
Allam F, Dao AT, Chugh G, Bohat R, Jafri F, Patki G, et al. Grape powder supplementation prevents oxidative stress-induced anxiety-like behavior, memory impairment, and high blood pressure in rats. J Nutr. 2013;143:835-42.
Dilberger B, Passon M, Asseburg H, Silaidos CV, Schmitt F, Schmiedl T, et al. Polyphenols and metabolites enhance survival in rodents and nematodes-impact of mitochondria. Nutrients. 2019;11:1886.
Murugaiyah V, Mattson MP. Neurohormetic phytochemicals: an evolutionary-bioenergetic perspective. Neurochem Int. 2015;89:271-80.
Asseburg H, Schäfer C, Müller M, Hagl S, Pohland M, Berressem D, et al. Effects of grape skin extract on age-related mitochondrial dysfunction, memory and life span in C57BL/6J mice. Neuromolecular Med. 2016;18:378-95.
Féart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302:638-48.
Scarmeas N, Stern Y, Tang M-X, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol. 2006;59:912-21.
Yusufov M, Weyandt LL, Piryatinsky I. Alzheimer's disease and diet: a systematic review. Int J Neurosci. 2017;127:161-75.
Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr (Bethesda, MD). 2016;7:889-904.
Feart C, Samieri C, Barberger-Gateau P. Mediterranean diet and cognitive health: an update of available knowledge. Curr Opin Clin Nutr Metab Care. 2015;18:51-62.
Trichopoulou A, Martínez-González MA, Tong TY, Forouhi NG, Khandelwal S, Prabhakaran D, et al. Definitions and potential health benefits of the Mediterranean diet: views from experts around the world. BMC Med. 2014;12:112.
Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84:1318-25.
Martínez-Lapiscina EH, Clavero P, Toledo E, San Julián B, Sanchez-Tainta A, Corella D, et al. Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. J Nutr Health Aging. 2013;17:544-52.
Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de La Torre R, Martínez-González MÁ, et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med. 2015;175:1094-103.
Bayram B, Ozcelik B, Grimm S, Roeder T, Schrader C, Ernst IMA, et al. A diet rich in olive oil phenolics reduces oxidative stress in the heart of SAMP8 mice by induction of Nrf2-dependent gene expression. Rejuvenation Res. 2012;15:71-81.
Fernández del Río L, Gutiérrez-Casado E, Varela-López A, Villalba JM. Olive oil and the hallmarks of aging. Molecules (Basel, Switzerland). 2016;21:163.
Angeloni C, Malaguti M, Barbalace M, Hrelia S. Bioactivity of olive oil phenols in neuroprotection. Int J Mol Sci. 2017;18:2230.
Gorzynik-Debicka M, Przychodzen P, Cappello F, Kuban-Jankowska A, Marino Gammazza A, Knap N, et al. Potential health benefits of olive oil and plant polyphenols. Int J Mol Sci. 2018;19:686.
Reutzel M, Grewal R, Silaidos C, Zotzel J, Marx S, Tretzel J, et al. Effects of Long-term treatment with a blend of highly purified olive Secoiridoids on cognition and brain ATP levels in aged NMRI mice. Oxid Med Cell Longev. 2018;2018:4070935.
Schaffer S, Podstawa M, Visioli F, Bogani P, Müller WE, Eckert GP. Hydroxytyrosol-rich olive mill wastewater extract protects brain cells in vitro and ex vivo. J Agric Food Chem. 2007;55:5043-9.
Schaffer S, Müller WE, Eckert GP. Cytoprotective effects of olive mill wastewater extract and its main constituent hydroxytyrosol in PC12 cells. Pharmacol Res. 2010;62:322-7.
Pantano D, Luccarini I, Nardiello P, Servili M, Stefani M, Casamenti F. Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. Br J Clin Pharmacol. 2017;83:54-62.
Casamenti F, Grossi C, Rigacci S, Pantano D, Luccarini I, Stefani M. Oleuropein alycone: a possible drug against degenerative conditions. In vivo evidence of its effectiveness against Alzheimer's disease. J Alzheimers Dis. 2015;45:679-88.
Casamenti F, Stefani M. Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. Expert Rev Neurother. 2017;17:345-58.
Grewal R, Reutzel M, Dilberger B, Hein H, Zotzel J, Marx S, et al. Purified oleocanthal and ligstroside protect against mitochondrial dysfunction in models of early Alzheimer's disease and brain ageing. Exp Neurol. 2020;328:113248.
Colizzi C. The protective effects of polyphenols on Alzheimer's disease: a systematic review. Alzheimer's Dementia. 2019;5:184-96.
Malar D, Devi K. Dietary polyphenols for treatment of Alzheimer's disease- future research and development. Curr Pharm Biotechnol. 2014;15:330-42.
Jayasena T, Poljak A, Smythe G, Braidy N, Münch G, Sachdev P. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease. Ageing Res Rev. 2013;12:867-83.
Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Gauthier S, et al. Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. World J Biol Psychiat. 2019;20:173-89.
Tajadini H, Saifadini R, Choopani R, Mehrabani M, Kamalinejad M, Haghdoost AA. Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: a 12-week randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2015;23:767-72.
Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, et al. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Hum Psychopharmacol. 2014;29:351-9.
Burns A, Perry E, Holmes C, Francis P, Morris J, Howes MJR, et al. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31:158-64.
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther. 2010;35:581-8.
Baum L, Lam CWK, Cheung SK-K, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28:110-3.
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry. 2003;74:863-6.
Wightman EL, Reay JL, Haskell CF, Williamson G, Dew TP, Kennedy DO. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br J Nutr. 2014;112:203-13.
Mollace V, Scicchitano M, Paone S, Casale F, Calandruccio C, Gliozzi M, et al. Hypoglycemic and hypolipemic effects of a new lecithin formulation of bergamot polyphenolic fraction: a double blind, randomized, placebo- controlled study. Endocr Metab Immune Disord Drug Targets. 2019;19:136-43.
Wang G, Wang L, Wang C, Qin L. Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease. Medicine. 2018;97:e0636.
Guo Q, Zhou Y, Wang C-J, Huang Y-M, Lee Y-T, Su MH, et al. An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain[®]) for treating moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013;28:363-70.
Remington R, Chan A, Lepore A, Kotlya E, Shea TB. Apple juice improved behavioral but not cognitive symptoms in moderate-to-late stage Alzheimer's disease in an open-label pilot study. Am J Alzheimers Dis Other Demen. 2010;25:367-71.
Heo J-H, Lee S-T, Chu K, Oh MJ, Park H-J, Shim JY, et al. An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimers disease. Eur J Neurol. 2008;15:865-8.
Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383-91.
Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation. 2017;14:1202.
DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012;11:511.
Hooshmand B, Mangialasche F, Kalpouzos G, Solomon A, Kåreholt I, Smith AD, et al. Association of vitamin B12, Folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal population-based study. JAMA Psychiat. 2016;73:606-13.
Madsen SK, Rajagopalan P, Joshi SH, Toga AW, Thompson PM. Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's disease neuroimaging initiative. Neurobiol Aging. 2015;36:S203-10.
Hooshmand B, Solomon A, Kåreholt I, Rusanen M, Hänninen T, Leiviskä J, et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. J Intern Med. 2012;271:204-12.
Gopinath B, Flood VM, Rochtchina E, Thiagalingam A, Mitchell P. Serum homocysteine and folate but not vitamin B 12 are predictors of CHD mortality in older adults. Eur J Prev Cardiolog. 2011;19:1420-9.
Bailey RL, Jun S, Murphy L, Green R, Gahche JJ, Dwyer JT, et al. High folic acid or folate combined with low vitamin B-12 status: potential but inconsistent association with cognitive function in a nationally representative cross-sectional sample of US older adults participating in the NHANES. Am J Clin Nutr. 2020;112:1547-57.
Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJPM, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100:657-66.
Hankey GJ, Ford AH, Yi Q, Eikelboom JW, Lees KR, Chen C, et al. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. Stroke. 2013;44:2232-9.
Mendonça N, Granic A, Mathers JC, Martin-Ruiz C, Wesnes KA, Seal CJ, et al. One-carbon metabolism biomarkers and cognitive decline in the very old: the Newcastle 85+ study. J Am Med Dir Assoc. 2017;18:806.e19-27.
Scott TM, Rogers G, Weiner DE, Livingston K, Selhub J, Jacques PF, et al. B-vitamin therapy for kidney transplant recipients lowers Homocysteine and improves selective cognitive outcomes in the randomized FAVORIT ancillary cognitive trial. J Prev Alzheimers Dis. 2017;4:174-82.
Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet (London, England). 2007;369:208-16.
de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27:592-600.
Zhang C, Luo J, Yuan C, Ding D. Vitamin B12, B6, or folate and cognitive function in community-dwelling older adults: a systematic review and meta-analysis. J Alzheimers Dis. 2020;77:781-94.
Kwok T, Wu Y, Lee J, Lee R, Yung CY, Choi G, et al. A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. Clin Nutr (Edinburgh, Scotland). 2020;39:2399-405.
Baroni L, Bonetto C, Rizzo G, Bertola C, Caberlotto L, Bazzerla G. Association between cognitive impairment and vitamin B12, Folate, and Homocysteine status in elderly adults: a retrospective study. J Alzheimers Dis. 2019;70:443-53.
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29:21-30.
Sonnenberg J, Luine VN, Krey LC, Christakos S. 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology. 1986;118:1433-9.
Landfield PW, Cadwallader-Neal L. Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Neurobiol Aging. 1998;19:469-77.
Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-9.
Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci. 2001;21:98-108.
Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, et al. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009;17:703-17.
Taghizadeh M, Talaei SA, Djazayeri A, Salami M. Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer's disease. Nutr Neurosci. 2014;17:172-7.
Yu J, Gattoni-Celli M, Zhu H, Bhat NR, Sambamurti K, Gattoni-Celli S, et al. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AβPP transgenic mice. J Alzheimers Dis. 2011;25:295-307.
Latimer CS, Brewer LD, Searcy JL, Chen K-C, Popović J, Kraner SD, et al. Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A. 2014;111:E4359-66.
Maretzke F, Bechthold A, Egert S, Ernst JB, van Melo Lent D, Pilz S, et al. Role of vitamin D in preventing and treating selected Extraskeletal diseases-An umbrella review. Nutrients. 2020;12:969.
Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012;79:1397-405.
Goodwill AM, Szoeke C. A systematic review and Meta-analysis of the effect of Low vitamin D on cognition. J Am Geriatr Soc. 2017;65:2161-8.
Pettersen JA, Fontes S, Duke CL. The effects of vitamin D insufficiency and seasonal decrease on cognition. Can J Neurol Sci. 2014;41:459-65.
Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis. 2013;37:147-71.
Pettersen JA. Vitamin D and executive functioning: are higher levels better? J Clin Exp Neuropsychol. 2016;38:467-77.
Darwish H, Zeinoun P, Ghusn H, Khoury B, Tamim H, Khoury SJ. Serum 25-hydroxyvitamin D predicts cognitive performance in adults. Neuropsychiatr Dis Treat. 2015;11:2217-23.
Nagel G, Herbolsheimer F, Riepe M, Nikolaus T, Denkinger MD, Peter R, et al. Serum vitamin D concentrations and cognitive function in a population-based study among older adults in South Germany. J Alzheimer's Dis. 2015;45:1119-26.
Lam V, Albrecht MA, Takechi R, Prasopsang P, Lee YP, Foster JK, et al. Serum 25-hydroxyvitamin D is associated with reduced verbal episodic memory in healthy, middle-aged and older adults. Eur J Nutr. 2016;55:1503-13.
Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, et al. Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr. 2017;17:16.
Pettersen JA. Does high dose vitamin D supplementation enhance cognition?: a randomized trial in healthy adults. Exp Gerontol. 2017;90:90-7.
Mokry LE, Ross S, Morris JA, Manousaki D, Forgetta V, Richards JB. Genetically decreased vitamin D and risk of Alzheimer disease. Neurology. 2016;87:2567-74.
Larsson SC, Traylor M, Markus HS, Michaëlsson K. Serum parathyroid hormone, 25-Hydroxyvitamin D, and risk of Alzheimer's disease: a Mendelian randomization study. Nutrients. 2018;10:1243.
Kueider AM, Tanaka T, An Y, Kitner-Triolo MH, Palchamy E, Ferrucci L, et al. State- and trait-dependent associations of vitamin-D with brain function during aging. Neurobiol Aging. 2016;39:38-45.
International Diabetes Federation IDF Diabetes Atlas Ninth edition 2019.
American Diabetes Association. Introduction: standards of medical Care in Diabetes-2018. Dia Care. 2018;41:S1-2.
Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-93.
Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Dia Care. 2017;40:136-54.
Singleton CK, Martin PR. Molecular mechanisms of thiamine utilization. Curr Mol Med. 2001;1:197-207.
Volvert M-L, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 2008;8:10.
Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 2007;50:2164-70.
Anwar A, Ahmed Azmi M, Siddiqui JA, Panhwar G, Shaikh F, Ariff M. Thiamine level in type I and type II diabetes mellitus patients: a comparative study focusing on hematological and biochemical evaluations. Cureus. 2020;12:e8027.
Page GLJ, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. Int J Clin Pract. 2011;65:684-90.
Hammes H-P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294-9.
Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem. 2006;281:9307-13.
Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol. 1997;52:319-20.
Ledermann H, Wiedey KD. Behandlung der manifesten diabetischen Polyneuropathie. Therapiewoche. 1989;39:1445-9.
Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther. 2005;43:71-7.
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116:600-5.
Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol. 1996;104:311-6.
Winkler G, Pál B, Nagybéganyi E, Ory I, Porochnavec M, Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung. 1999;49:220-4.
Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-50.
Matsugo S, Han D, Tritschler HJ, Packer L. Decomposition of alpha-lipoic acid derivatives by photoirradiation-formation of dihydrolipoic acid from alpha-lipoic acid. Biochem Mol Biol Int. 1996;38:51-9.
Rochette L, Ghibu S, Muresan A, Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015;93:1021-7.
Stirban A. Drugs for the treatment of diabetes complications. Zycose: a new player in the field? Drugs Today (Barc). 2008;44:783-96.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-25.
Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Dia Care. 2004;27:2178-83.
Jacob S, Henriksen EJ, Schiemann AL, Simon I, Clancy DE, Tritschler HJ, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung. 1995;45:872-4.
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Med. 2004;21:114-21.
Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Med. 2016;33:1466-76.
Amato Nesbit S, Sharma R, Waldfogel JM, Zhang A, Bennett WL, Yeh HC, et al. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2019;35:15-25.
Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, et al. Preventing complications and treating symptoms of diabetic peripheral neuropathy. Rockville (MD); Agency for Healthcare Research and Quality (US); 2017.
Rutkove S, McIlduff. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Therapeutics and Clinical Risk Management. 2011;7:377-85.
Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167-84.
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Dia Care. 2006;29:2365-70.
Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy. Treat Endocrinol. 2004;3:173-89.
Tang J, Wingerchuk DM, Crum BA, Rubin DI, Demaerschalk BM. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007;13:164-7.
Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α-Lipoic acid over 4 years in diabetic polyneuropathy. Dia Care. 2011;34:2054-60.
Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia. 2008;51:1930-2.
Popa AR, Bungau S, Vesa CM, Bondar AC, Pantis C, Maghiar O, et al. Evaluating the efficacy of the treatment with benfotiamine and alpha-lipoic acid in distal symmetric painful diabetic polyneuropathy. Rev Chim. 2019;70:3108-14.